Align Technology Inc (ALGN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Align Technology Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 169.20 $ — 61% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 2.6% failed
- More than 10% revenue growth is expected for the coming year 4.4% failed
- Share count grows by less than 3% a year -2.5% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 13.1% failed
- Gross margin at 40% or higher and without meaningful erosion 68.3% passed
- Goodwill from acquisitions does not grow faster than revenue 7.9% failed
- Net debt below twice EBITDA 980 m net cash passed
- Operating cash flow covers the profits of the last three years 840 m passed
- Return on capital at 15% or higher, or up versus two years ago 14.3% failed
- Insiders hold at least 10% or are net buyers 6.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 23.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 18
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 11.28 | 11.12 – 11.70 | 4,169 | 7.3% | 16 |
| 12/31/2027 | 12.53 | 12.17 – 13.24 | 4,337 | 11.1% | 16 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.39 | -14.80 | 995 | 4.00 | 10.40 | 286 | 263 |
| 2025: Q1 | 1.27 | -9.20 | 979 | -1.80 | 9.50 | 53 | 27 |
| 2025: Q2 | 1.72 | 33.70 | 1,012 | -1.60 | 12.30 | 129 | 154 |
| 2025: Q3 | 0.78 | -49.50 | 996 | 1.80 | 5.70 | 189 | 122 |
| 2025: Q4 | 1.89 | 35.70 | 1,048 | 5.30 | 13.00 | 223 | 290 |
| 2026: Q1 | 1.57 | 24.30 | 1,040 | 6.20 | 10.80 | 151 | 120 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,080 | 249 | 190 | 2.33 | 248 | 995 | 1,396 |
| 2017 | 1,473 | 354 | 231 | 2.83 | 439 | 1,150 | 1,778 |
| 2018 | 1,966 | 467 | 400 | 4.92 | 555 | 1,253 | 2,052 |
| 2019 | 2,407 | 542 | 443 | 5.53 | 747 | 1,346 | 2,501 |
| 2020 | 2,472 | 387 | 1,776 | 22.41 | 662 | 3,234 | 4,830 |
| 2021 | 3,953 | 976 | 772 | 9.69 | 1,173 | 3,623 | 5,942 |
| 2022 | 3,735 | 643 | 362 | 4.61 | 569 | 3,601 | 5,948 |
| 2023 | 3,862 | 643 | 445 | 5.81 | 786 | 3,630 | 6,084 |
| 2024 | 3,999 | 608 | 421 | 5.62 | 738 | 3,852 | 6,215 |
| 2025 | 4,035 | 616 | 410 | 5.65 | 593 | 4,049 | 6,234 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Align Technology, Inc. bietet Invisalign-Klaraligner, Vivera-Retainer und iTero-Intraoralscanner und -dienste in den USA, der Schweiz und international an.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 20,290 |
| Headquarters | Tempe, AZ |
| Address | 410 North Scottsdale Road, 85288 Tempe, United States |
| Phone | 602 742 2000 |
| Website | aligntech.com |
| IPO Date | 26. Jan 2001 |
| ISIN | US0162551016 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Joseph M. Hogan | President, CEO & Director | 1957 |
| John F. Morici | CFO & Executive VP of Global Finance | 1967 |
| Zelko Relic | Executive VP & CTO | 1965 |
| Shirley Stacy | Vice President of Corporate Communications & Investor Relations | – |
| Richardson Jaime Holte | Executive Vice President of Global Human Resources | – |
| Sreelakshmi Kolli | Executive VP and Chief Product & Digital Officer | 1975 |
| Srini Kaza | Executive Vice President of Research & Development | – |
| Mitra Derakhshan | Executive VP, Chief Clinical Officer, Global Treatment Planning & Clinical Services | – |
| David Carr | Executive VP and MD of EMEA | – |
| Frank Quinn | Executive VP & MD of Americas Region | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.